Walmart's Sale Of Asda Group Likely To Get Regulatory Approval

The sale of Asda Stores Ltd., owned by retail giant Walmart Inc. (WMT), seems likely to be completed soon, after the consortium purchasing the British supermarket chain said that the British regulator Competition and Markets Authority said there was "reasonable grounds" it would accept amended proposals made by the consortium.

U.K.-based Zuber Issa, Mohsin Issa and offered to divest 27 EG Group petrol filling stations in order for the deal to be completed.

The deal to buy Asda, the UK's third-largest supermarket chain, for $6.8 billion pounds, was announced in October last year. However, the regulator found concerns in 37 areas of the UK after the brothers and TDR Capital took over Asda and its 323 petrol stations.

The CMA launched a probe into the acquisition last December to see if the deal would lead to a "substantial lessening of competition". According to CMA, the purchase of Asda could lead to higher petrol prices in some parts of the country.

The brothers will now sell 27 of the 395 EG Group petrol filling stations they own.

"The CMA considers that there are reasonable grounds for believing that the undertakings offered jointly by Mr Zuber Issa, Mr Mohsin Issa and TDR Capital, might be accepted by the CMA under the Enterprise Act 2002," CMA said in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
Follow RTT